Andrew J. Cutler, MD
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York; Neuroscience Education Institute, Carlsbad, California
Original Research
Amphetamine Extended-Release Tablets for Adult ADHD
July 20, 2022
Treating attention-deficit/hyperactivity disorder (ADHD) in adults can improve long-term outcomes, such as reducing suicidal behavior and mortality. This study evaluated the efficacy and safety of amphetamine extended-release tablets in...
Original Research
Efficacy and Safety of AR19 in Adults With ADHD
August 24, 2021
Misuse of stimulant medications prescribed for attention-deficit/hyperactivity disorder (ADHD) can have adverse medical outcomes. This study tested the safety and efficacy of AR19, a manipulation-resistant formulation of amphetamine, in...
Original Research
Response and Remission with DR/ER-MPH
June 22, 2021
Delayed-release and extended-release methylphenidate (DR/ER-MPH) has shown marked improvement in ADHD symptoms and functional impairment. This post hoc analysis examined response and remission thresholds for DR/ER-MPH in the context...
Original Research
Valbenazine for Tardive Dyskinesia: Results From the KINECT 3 Study
December 18, 2018
Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
Article
Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories
June 11, 2015
Reducing functional impairment in patients with major depressive disorder is critical for optimizing treatment outcomes and achieving long-term wellness. In this post hoc analysis, improvement in functional impairment in...
